Mammary stem cells and progenitors: targeting the roots of breast cancer for prevention
Open Access
- 21 June 2019
- journal article
- review article
- Published by Springer Science and Business Media LLC in The EMBO Journal
- Vol. 38 (14), e100852
- https://doi.org/10.15252/embj.2018100852
Abstract
Breast cancer prevention is daunting, yet not an unsurmountable goal. Mammary stem and progenitors have been proposed as the cells‐of‐origin in breast cancer. Here, we present the concept of limiting these breast cancer precursors as a risk reduction approach in high‐risk women. A wealth of information now exists for phenotypic and functional characterization of mammary stem and progenitor cells in mouse and human. Recent work has also revealed the hormonal regulation of stem/progenitor dynamics as well as intrinsic lineage distinctions between mammary epithelial populations. Leveraging these insights, molecular marker‐guided chemoprevention is an achievable reality.Keywords
Funding Information
- Canadian Cancer Society Research Institute (702294, 705458)
- Canadian Institutes of Health Research
This publication has 218 references indexed in Scilit:
- Amphiregulin mediates progesterone-induced mammary ductal development during pubertyBreast Cancer Research, 2013
- Lgr5-Expressing Cells Are Sufficient and Necessary for Postnatal Mammary Gland OrganogenesisCell Reports, 2013
- R Loops: From Transcription Byproducts to Threats to Genome StabilityMolecular Cell, 2012
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- ALDH1 Is a Marker of Normal and Malignant Human Mammary Stem Cells and a Predictor of Poor Clinical OutcomeCell Stem Cell, 2007
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Spectrum of Mutations in BRCA1, BRCA2, CHEK2, and TP53 in Families at High Risk of Breast CancerJAMA, 2006
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002